GR 79236

Drug Profile

GR 79236

Latest Information Update: 03 Jul 2003

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Pain; Reperfusion injury; Type 2 diabetes mellitus

Most Recent Events

  • 03 Jul 2003 A clinical study has been added to the adverse events and Headache and migraine pharmacodynamics sections
  • 24 Aug 1999 Discontinued-I for Hyperlipidaemia in United Kingdom (Unknown route)
  • 24 Aug 1999 Discontinued-I for Pain in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top